SOURCE: Micromet Inc.

July 31, 2006 04:11 ET

Micromet, Inc. to Host Conference Call and Live Webcast to Discuss Second Quarter 2006 Financial Results

CARLSBAD, GERMANY -- (MARKET WIRE) -- July 31, 2006 --



Carlsbad, CA, - July 31, 2006 - Micromet, Inc. (NASDAQ: MITI), a transatlantic biotechnology company focused on the development of antibody-based pharmaceutical products for the treatment of cancer, autoimmune and inflammatory diseases, will host a conference call and live webcast on Wednesday, August 9, 2006, at 10:00am Eastern Time (04:00pm Central European Summer Time) to discuss the company's financial results for the second quarter ended June 30, 2006.

The conference call will be webcast simultaneously over the Internet. To listen, please visit Micromet's corporate website at www.micromet-inc.com. The webcast will be archived for one year. Alternatively, callers may participate in the conference call by dialing 866-314-4483 (domestic), +1-617-213-8049 (international) or +44-207-365-8426 (United Kingdom). The passcode for the conference call is MICROMET.

A replay of the call can be accessed by dialing 888-286-8010 (domestic), +1-617-801-6888 (international) or +44-207-365-8427 (United Kingdom). The passcode for the replay is 19112008.



Contact Information

Investors: Ines-Regina Buth
(760) 494-4235 (US)
+49 (0)89 895277 221 (Europe)
ines.buth@micromet-inc.com

Media Europe: Evelyn Wolf
+49 (0)89 895277 220
evelyn.wolf@micromet-inc.com

Media US: Susan Noonan
(212) 966-3650
susan@sanoonan.com

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company with a focus on the development of novel, proprietary antibody-based products for cancer and inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Adecatumumab (MT201), a recombinant human monoclonal antibody, is being evaluated in Phase 2 clinical trials for the treatment of patients with breast cancer and prostate cancer. MT103 is being studied in a Phase 1 clinical trial for the treatment of patients with Non Hodgkin Lymphoma. Micromet has established a drug development platform based on its BiTE® technology, a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Micromet has established collaborations with MedImmune, Inc. and Serono.





Copyright © Hugin ASA 2006. All rights reserved.

Contact Information